National Robotics-Assisted Radical Prostatectomy Database
RASOR
1 other identifier
observational
10,000
1 country
8
Brief Summary
In Australia, nearly 70 men are diagnosed with Prostate cancer every day. Prostate removal (Radical Prostatectomy) is the proven treatment option to control cancer spread. Most of the prostate removal surgeries are done using robots. Robotic assisted prostate removal surgeries have been invented to minimise the risk of side effects post-surgery. Doctors prefer the robots over open surgery as there are benefits to patients (shorter hospital stays, lesser blood loss and better quality of life) and surgeons (better dexterity, improved field of vision and less pain). However, the cost of the robot outweighs the benefits at present and there is very less information concerning the long-term outcomes for patients. Studies conducted so far are small scale studies and the results from these studies cannot be generalized to the population at large in Australia. So, there is need for a largescale study that will look at the long-term outcomes and the factors that impact robotic surgeries across the metropolitan and rural hospital sectors. Hence, this comprehensive database has been setup to collaborate with major hospitals, across metropolitan and rural areas in Australia. Through this database, researchers will be able to explore the diagnostic pathway for Prostate cancer and understand the long-term benefits of robotic surgery through patient reported questionnaires. Outcomes from this database will also help compare the quality of care against other powerhouses of robotic surgery. Eventually, the database aims to standardize diagnostic pathways and clinical notes that are the same across different hospitals conducting robotic-assisted surgeries for Prostatectomy and improve care for prostate cancer patients across the country.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2024
Longer than P75 for all trials
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 19, 2024
CompletedFirst Posted
Study publicly available on registry
February 28, 2024
CompletedStudy Start
First participant enrolled
July 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2050
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2050
August 26, 2024
August 1, 2024
26.4 years
February 19, 2024
August 22, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
To provide a standardized framework, enabling robust evidence strengthening & analyses, trend identification, and the formulation of evidence-based guidelines for the individualized management of PCa.
Standardize notes that are the same across different hospitals conducting robotic-assisted surgeries for prostatectomy.
At baseline, 4 weeks, 6 months, 12 months, 24 months and 36 months post-surgery.
Secondary Outcomes (3)
Patient reported quality of life outcome measures
At baseline, 4 weeks, 6 months, 12 months, 24 months and 36 months post-surgery.
Surgical
At baseline, 4 weeks, 6 months, 12 months, 24 months and 36 months post-surgery.
Oncological
4 weeks, 6 months, 12 months, 24 months and 36 months post-surgery.
Eligibility Criteria
The database will entail recruitment of retrospective and prospective patient cohorts to collect and analyse data. Retrospective data from the last five years will be obtained from the medical records. Prospective data will be collected from each participating site.
You may qualify if:
- To be eligible to participate in this database, an individual must meet all of the following criteria:
- Individuals who consent to participate,
- within the age range of 18 to 90 years,
- confirmed diagnosis of localized prostate cancer (PCa)
- patients receiving medical attention at hospitals engaged in collaborative efforts with the designated database.
You may not qualify if:
- Participants are not eligible to take part in the database:
- Individuals who have not undergone robotic surgery for prostatectomy or TP biopsy. ,
- without a diagnosis of prostate cancer or
- who decline to provide consent for the collection of their health information
- Under the age of 18 years.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Melbourne Healthlead
- Peter MacCallum Cancer Centre, Australiacollaborator
- Epworth Healthcarecollaborator
- St Vincent's Hospitalcollaborator
- Austin Healthcollaborator
- Barwon Healthcollaborator
- Ballarat Health Servicescollaborator
- Western Health, Australiacollaborator
Study Sites (8)
Ballarat Health
Ballarat, Victoria, 3350, Australia
Barwon health
Geelong, Victoria, 3220, Australia
Austin Healthcare
Melbourne, Victoria, 2084, Australia
E.J Whitten Prostate Cancer Centre, Epworth Healthcare
Melbourne, Victoria, 3002, Australia
St. Vincent's Private Hospital
Melbourne, Victoria, 3002, Australia
Western Heath
Melbourne, Victoria, 3011, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3050, Australia
Royal Melbourne Hospital
Melbourne, Victoria, 3050, Australia
Related Publications (4)
Perera S, Fernando N, O'Brien J, Murphy D, Lawrentschuk N. Robotic-assisted radical prostatectomy: learning curves and outcomes from an Australian perspective. Prostate Int. 2023 Mar;11(1):51-57. doi: 10.1016/j.prnil.2022.10.002. Epub 2022 Oct 29.
PMID: 36910896BACKGROUNDFridriksson JO, Folkvaljon Y, Lundstrom KJ, Robinson D, Carlsson S, Stattin P. Long-term adverse effects after retropubic and robot-assisted radical prostatectomy. Nationwide, population-based study. J Surg Oncol. 2017 Sep;116(4):500-506. doi: 10.1002/jso.24687. Epub 2017 Jun 7.
PMID: 28591934BACKGROUNDTiruye T, O'Callaghan M, Moretti K, Jay A, Higgs B, Santoro K, Boyle T, Ettridge K, Beckmann K. Patient-reported functional outcome measures and treatment choice for prostate cancer. BMC Urol. 2022 Nov 5;22(1):169. doi: 10.1186/s12894-022-01117-1.
PMID: 36335325BACKGROUNDChandrasekar T, Tilki D. Prostate cancer: Comparing quality of life outcomes after prostate cancer treatment. Nat Rev Urol. 2017 Jul;14(7):396-397. doi: 10.1038/nrurol.2017.81. Epub 2017 Jun 13. No abstract available.
PMID: 28607497BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
February 19, 2024
First Posted
February 28, 2024
Study Start
July 1, 2024
Primary Completion (Estimated)
December 1, 2050
Study Completion (Estimated)
December 1, 2050
Last Updated
August 26, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will not share
* Patient data will only be transferred and analysed in a coded form by mentioned investigators. * Transferring patient data will require host organisation's formal approval * Individual patients will not be identifiable from the presented or published material. * The institution and the researcher must comply with all relevant laws and standards in relation to the use of the material. * The institution and researcher must not use the material for any purpose other than the specified research or other purposes expressly permitted under the terms of the Agreement. * Data linkage across sites will be set up when necessary. Once linkage has been completed, identifiers will be removed from the data to be used in the research, unless consent has been given for its identifiable use.